{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-018324","form_type":"8-K","ticker":"PALI","cik":"0001357459","company_name":"PALISADE BIO, INC.","filed_at":"2025-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.220342+00:00","generated_at":"2026-05-17T03:31:05.882490+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Palisade Bio regains Nasdaq minimum bid price compliance; reports $133.3M cash","bullets":["Received Nasdaq compliance letter confirming regained bid price requirement; matter closed as of Oct 15, 2025.","Cash and cash equivalents approx. $133.3 million as of Oct 15, 2025.","Outstanding common shares: 133,002,572; pre-funded warrants for 73,271,424 shares.","No other material corporate updates provided in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-018324","json":"https://secwatch.observer/filing/0001493152-25-018324.json","markdown":"https://secwatch.observer/filing/0001493152-25-018324.md","text":"https://secwatch.observer/filing/0001493152-25-018324.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357459/000149315225018324/0001493152-25-018324-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357459/000149315225018324/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:31:05.882490+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}